Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer

Gregory P Swanson, William Jones, Chul S Ha, Carol A. Jenkins, Addanki P Kumar, Joseph W Basler

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Phellodendron amurense bark extract (Nexrutine®) has shown a favorable effect on prostate cancer in vivo and in vitro. We evaluated its tolerance in patients undergoing surgery or radiation for prostate cancer. Patients received Nexrutine® orally (500 mg tid) either 1 to 2 months preoperatively or 1 to 2 months prior to and with radiation therapy. Common Terminology Criteria for Adverse Events were used to measure tolerance. In total, 21 patients (9 surgery and 12 radiation) underwent treatment. During the Nexrutine® alone component, there were two transient grade 3 toxicities (hypokalemia and urinary incontinence). There was no grade 4 toxicity. For the combined Nexrutine® and radiation component, no additional patients suffered a grade 3 toxicity. All the toxicities were transient. By the end of the neoadjuvant treatment, 81% of the patients had a decline in prostate-specific antigen. This is the first report of patients with prostate cancer being treated with P. amurense bark extract, and it was very well tolerated. Toxicities were minimal and self-limited. This compound can be safely used in further evaluation of a treatment effect on cancer.

Original languageEnglish (US)
Pages (from-to)40-42
Number of pages3
JournalPhytotherapy Research
Volume29
Issue number1
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Phellodendron
Prostatic Neoplasms
Radiation
Neoadjuvant Therapy
Hypokalemia
Urinary Incontinence
Prostate-Specific Antigen
Terminology
Nexrutine
Radiotherapy
Therapeutics

Keywords

  • Combined modality
  • Nexrutine®
  • Phellodendron amurense extract
  • Prostate cancer
  • Prostatectomy
  • Radiation therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer. / Swanson, Gregory P; Jones, William; Ha, Chul S; Jenkins, Carol A.; Kumar, Addanki P; Basler, Joseph W.

In: Phytotherapy Research, Vol. 29, No. 1, 2015, p. 40-42.

Research output: Contribution to journalArticle

Swanson, Gregory P ; Jones, William ; Ha, Chul S ; Jenkins, Carol A. ; Kumar, Addanki P ; Basler, Joseph W. / Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer. In: Phytotherapy Research. 2015 ; Vol. 29, No. 1. pp. 40-42.
@article{7c8c5f879b2b4c2996f3af7661096dda,
title = "Tolerance of Phellodendron amurense bark extract (Nexrutine{\circledR}) in patients with human prostate cancer",
abstract = "Phellodendron amurense bark extract (Nexrutine{\circledR}) has shown a favorable effect on prostate cancer in vivo and in vitro. We evaluated its tolerance in patients undergoing surgery or radiation for prostate cancer. Patients received Nexrutine{\circledR} orally (500 mg tid) either 1 to 2 months preoperatively or 1 to 2 months prior to and with radiation therapy. Common Terminology Criteria for Adverse Events were used to measure tolerance. In total, 21 patients (9 surgery and 12 radiation) underwent treatment. During the Nexrutine{\circledR} alone component, there were two transient grade 3 toxicities (hypokalemia and urinary incontinence). There was no grade 4 toxicity. For the combined Nexrutine{\circledR} and radiation component, no additional patients suffered a grade 3 toxicity. All the toxicities were transient. By the end of the neoadjuvant treatment, 81{\%} of the patients had a decline in prostate-specific antigen. This is the first report of patients with prostate cancer being treated with P. amurense bark extract, and it was very well tolerated. Toxicities were minimal and self-limited. This compound can be safely used in further evaluation of a treatment effect on cancer.",
keywords = "Combined modality, Nexrutine{\circledR}, Phellodendron amurense extract, Prostate cancer, Prostatectomy, Radiation therapy",
author = "Swanson, {Gregory P} and William Jones and Ha, {Chul S} and Jenkins, {Carol A.} and Kumar, {Addanki P} and Basler, {Joseph W}",
year = "2015",
doi = "10.1002/ptr.5221",
language = "English (US)",
volume = "29",
pages = "40--42",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer

AU - Swanson, Gregory P

AU - Jones, William

AU - Ha, Chul S

AU - Jenkins, Carol A.

AU - Kumar, Addanki P

AU - Basler, Joseph W

PY - 2015

Y1 - 2015

N2 - Phellodendron amurense bark extract (Nexrutine®) has shown a favorable effect on prostate cancer in vivo and in vitro. We evaluated its tolerance in patients undergoing surgery or radiation for prostate cancer. Patients received Nexrutine® orally (500 mg tid) either 1 to 2 months preoperatively or 1 to 2 months prior to and with radiation therapy. Common Terminology Criteria for Adverse Events were used to measure tolerance. In total, 21 patients (9 surgery and 12 radiation) underwent treatment. During the Nexrutine® alone component, there were two transient grade 3 toxicities (hypokalemia and urinary incontinence). There was no grade 4 toxicity. For the combined Nexrutine® and radiation component, no additional patients suffered a grade 3 toxicity. All the toxicities were transient. By the end of the neoadjuvant treatment, 81% of the patients had a decline in prostate-specific antigen. This is the first report of patients with prostate cancer being treated with P. amurense bark extract, and it was very well tolerated. Toxicities were minimal and self-limited. This compound can be safely used in further evaluation of a treatment effect on cancer.

AB - Phellodendron amurense bark extract (Nexrutine®) has shown a favorable effect on prostate cancer in vivo and in vitro. We evaluated its tolerance in patients undergoing surgery or radiation for prostate cancer. Patients received Nexrutine® orally (500 mg tid) either 1 to 2 months preoperatively or 1 to 2 months prior to and with radiation therapy. Common Terminology Criteria for Adverse Events were used to measure tolerance. In total, 21 patients (9 surgery and 12 radiation) underwent treatment. During the Nexrutine® alone component, there were two transient grade 3 toxicities (hypokalemia and urinary incontinence). There was no grade 4 toxicity. For the combined Nexrutine® and radiation component, no additional patients suffered a grade 3 toxicity. All the toxicities were transient. By the end of the neoadjuvant treatment, 81% of the patients had a decline in prostate-specific antigen. This is the first report of patients with prostate cancer being treated with P. amurense bark extract, and it was very well tolerated. Toxicities were minimal and self-limited. This compound can be safely used in further evaluation of a treatment effect on cancer.

KW - Combined modality

KW - Nexrutine®

KW - Phellodendron amurense extract

KW - Prostate cancer

KW - Prostatectomy

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84964241174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964241174&partnerID=8YFLogxK

U2 - 10.1002/ptr.5221

DO - 10.1002/ptr.5221

M3 - Article

VL - 29

SP - 40

EP - 42

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 1

ER -